Loading
Post Acute COVID 19 Syndrome / Baricitinib 4 MG · Phase 3 Trial
ClinicalTrials.gov · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a withdrawn Phase 3 trial registration for baricitinib in long COVID with neurocognitive or cardiopulmonary symptoms. No results are reported in this registry record, and the study was not completed. This record documents only the planned intervention and monitoring framework, not any clinical evidence.
Phase 3, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Post-Acute COVID-19 Syndrome; age from 18 Years. Intervention: Intervention #1. Compared with: Placebo — Placebo Comparator. 6 sites: United States.
This is a withdrawn Phase 3 trial registration for baricitinib in long COVID with neurocognitive or cardiopulmonary symptoms. No results are reported in this registry record, and the study was not completed. This record documents only the planned intervention and monitoring framework, not any clinical evidence.
No efficacy, safety, or adverse event data are available.
No clinical impact can be determined from this withdrawn trial registry record. Clinicians should not base any practice decisions on this registration, as no efficacy or safety results were generated.
This is a withdrawn Phase 3 trial registration with no results posted; the study was not completed and therefore provides no evidence of efficacy or safety.
As stated by the source record.
Quoted from the source exactly as published.
No clinical impact can be determined from this withdrawn trial registry record. Clinicians should not base any practice decisions on this registration, as no efficacy or safety results were generated.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05858515). This is a study registration, not published results. Lead sponsor: Vanderbilt University Medical Center. Recruitment status: WITHDRAWN. Phase: PHASE3. Study type: INTERVENTIONAL. Conditions: Post-Acute COVID-19 Syndrome. Interventions: DRUG: Baricitinib 4 MG; DRUG: Placebo. Primary outcome measures: Enrollment , 6 months; Diversity in enrollment , 6 months; Study drug prescribed , 9 months; Study withdrawals , 18 months; Adverse event reporting , 18 months; Study dosing , 9 months; Study completion , 18 months. Brief summary: REVERSE-LC is a phase 3 trial of baricitinib versus placebo in adults with neurocognitive impairment (a form of Alzheimer's Disease and Related Dementias or ADRD) or cardiopulmonary symptoms due to Long COVID.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.